1. Home
  2. RYTM vs SXT Comparison

RYTM vs SXT Comparison

Compare RYTM & SXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

N/A

Current Price

$115.20

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Logo Sensient Technologies Corporation

SXT

Sensient Technologies Corporation

N/A

Current Price

$116.30

Market Cap

5.5B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
RYTM
SXT
Founded
2008
1882
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Chemicals
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
6.3B
5.5B
IPO Year
2017
1994

Fundamental Metrics

Financial Performance
Metric
RYTM
SXT
Price
$115.20
$116.30
Analyst Decision
Strong Buy
Buy
Analyst Count
19
5
Target Price
$140.12
★ $143.60
AVG Volume (30 Days)
★ 1.5M
513.7K
Earning Date
11-03-2026
10-30-2026
Dividend Yield
N/A
★ 1.41%
EPS Growth
★ 28.34
7.48
EPS
N/A
★ 3.37
Revenue
N/A
★ $1,396,499,000.00
Revenue This Year
$73.80
$11.52
Revenue Next Year
$73.86
$12.32
P/E Ratio
★ N/A
$34.59
Revenue Growth
★ N/A
N/A
52 Week Low
$74.50
$82.60
52 Week High
$122.20
$138.82

Technical Indicators

Market Signals
Indicator
RYTM
SXT
Relative Strength Index (RSI) 65.94 35.22
Support Level $82.31 $108.43
Resistance Level $119.75 $131.05
Average True Range (ATR) 6.84 5.64
MACD 2.19 -0.84
Stochastic Oscillator 94.00 41.94

Price Performance

Historical Comparison
RYTM
SXT

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About SXT Sensient Technologies Corporation

Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. Its principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's reportable segments are: Flavors & Extracts, which derive key revenue, Color, Asia Pacific, and Corporate and Other. Geographically, the company generates maximum revenue from North America, followed by Europe, Asia-Pacific, and other regions.

Share on Social Networks: